FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)

View source ↗

Summary

FDA approves a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• APTIOM (Eslicarbazepine acetate)

Snippet

SUPPL AP for APTIOM (ESLICARBAZEPINE ACETATE)